Monoclonal Antibody therapy value in the Global Biotechnology Industry expected to increase.

Sales of monoclonal antibodies will reach $5 billion in 2003, an increase of 27% from 2001ís figures. This in-depth report will tell you.Monoclonal Antibodies 2003 assesses the financial state of this burgeoning market and provides vital market share information for the key products in the class which is vital to those considering entering this growing field.

(PRWEB) November 16, 2003 --Research and Markets announces the addition of "Monoclonal Antibodies 2003: Meeting Clinical and Financial Expectations" to their offerings:

The recent success of a number of new monoclonal antibody therapies suggests a resurgence in the biotechnology industry that is set to be realized in 2003 and the coming years. Drugs such as Genentech's Rituxan and Johnson & Johnson's Remicade are helping to pave the way. Sales in the billions of dollars highlight the clinical efficacy of antibody therapy for serious long-term conditions such as arthritis and Crohn's disease. Moreover, potential is quite vast as more and more antibody products are being evaluated for cancer indications.

Monoclonal Antibodies 2003: Meeting Clinical and Financial Expectations includes the important information that is vital to those considering entering this growing field.

The Financial state of the monoclonal antibody therapy market and five year forecasts for the market Research and development trends and pipeline timelines are included as well as profiles of the key biotech players in the monoclonal antibody market

In 2002, monoclonal antibody therapy represents approximately 16% of the value of the total global biotechnology industry. This percentage is rising every year and only by reading this unique report will you fully understand what it will be by 2008.

Sales of monoclonal antibodies will reach $5 billion in 2003, an increase of 27% from 2001ís figures. But what will they be in 2007 - you should know! This in-depth report will tell you.Monoclonal Antibodies 2003 assesses the financial state of this burgeoning market and provides vital market share information for the key products in the class. In addition, five year forecasts are provided for the leading antibody therapies on the market as well as for potential blockbusters still in the R&D pipeline.

A special visiongain Analysis chapter delves into the manufacturing capacity issues that are significant growth-limiting factors for this class of drugs. New production models, such as transgenic plants and animals are discussed at length in order to better determine whether production needs can be met in the future. Visiongain also provides an exhaustive list of company profiles for the contract manufacturing industry.

Analysis includes the use of charts and graphs measuring product growth and trends within the monoclonal antibody marketplace. Company-specific information, including sales and revenue figures, licensing arrangements, collaborations, and research and development trends is provided throughout the report.

For a complete index of this report click on http://www.researchandmarkets.com/reports/40114

About Research and Markets Ltd.
Research and Markets Ltd. are Europe's largest resource for market research. R&M distribute thousands of major research publications from the world's leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com
###